Dizal Pharmaceutical Co.,Ltd. (SH: 688192) has issued a stock price fluctuation announcement. The company recently entered into a licensing agreement with AstraZeneca UK Limited, granting AstraZeneca the exclusive global rights to develop and commercialize Sunvozertinib®. As of the date of the announcement's disclosure, the transaction still requires approval from the company's shareholders' meeting. Its final effectiveness is contingent upon meeting customary closing conditions and obtaining necessary approvals, including from antitrust regulatory authorities and other relevant agencies in overseas jurisdictions. There is uncertainty regarding whether the Licensing Agreement will ultimately come into effect.